SEARCH

SEARCH BY CITATION

References

  • 1
    O’Brien E. Ambulatory blood pressure measurement. The case for implementation in primary care. Hypertension 2008; 51: 143541.
  • 2
    Floras JS. Ambulatory blood pressure: facilitating individualized assessment of cardiovascular risk. J Hypertens 2007; 25: 15658.
  • 3
    O’Brien E. The value of 24-hour blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Topics 2011; In press.
  • 4
    O’Brien E, Fitzgerald D. The history of indirect blood pressure measurement. In O’BrienE, O’MalleyK, eds. Blood Pressure Measurement. Birkenhager WH, Reid JL, eds. Handbook of Hypertension. Amsterdam: Elsevier, 1991; 154.
  • 5
    Bevan AI, Honour AT, Stott FH. Direct arterial pressure recording in unrestricted man. Clin Sci 1969; 36: 32944.
  • 6
    Mann S, Jones RI, Millar-Craig MW, Wood C, Gould BA, Raftery ER. The safety of ambulatory intra-arterial pressure monitoring: a clinical audit of 1000 studies. Int J Cardiol 1984; 5: 58597.
  • 7
    O’Brien E, Petrie J, Littler W et al. The British Hypertension Society Protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems. J Hypertens 1990; 8: 60719.
  • 8
    Fitzgerald DJ, O’Callaghan WO, McQuaid R, O’Malley K, O’Brien E. Accuracy and reliability of two indirect ambulatory blood pressure recorders: Remler M2000 and Cardiodyne Sphygmolog. Br Heart J 1982; 48: 5729.
  • 9
    O’Brien E, Sheridan J, Browne T, Conroy R, O’Malley K. Validation of the SpaceLabs 90202 ambulatory blood pressure recorder. J Hypertens 1989; 7(suppl6): S388.
  • 10
    Parati G, Stergiou GS, Asmar R et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26: 150530.
  • 11
    Pickering TG, Shimbo D, Haas D. Ambulatory blood pressure monitoring. N Engl J Med 2006; 354: 236874.
  • 12
    O’Brien E, Asmar R, Beilin L et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 82148.
  • 13
    O’Brien E. Ambulatory blood pressure monitoring: 24-hour blood pressure control as a therapeutic goal for improving cardiovascular prognosis. Medicographia 2010; 32: 2419.
  • 14
    Dolan E, Stanton A, Thijs L et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin outcome study. Hypertension 2005; 46: 15661.
  • 15
    O’Brien E. Is the case for ABPM as a routine investigation in clinical practice not overwhelming? Hypertension 2007; 50: 2846.
  • 16
    Logan AG. Ambulatory blood pressure monitoring: its time to move on! J Hypertens 2010; 28: 20002.
  • 17
    de la Sierra A, Redon J, Banegas JR et al. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 2009; 53: 46672.
  • 18
    Krakoff LR. Cost–effectiveness of ambulatory BP: a reanalysis. Hypertension 2006; 47: 2934.
  • 19
    Garret BN, Kaplan N. Ambulatory blood pressure monitoring: a question of now and the future. J Clin Hypertens 1987; 3: 37880.
  • 20
    O’Brien E, Atkins N, Stergiou G et al. European Society of Hypertension International Protocol for the validation of blood pressure measuring devices in adults. 2010 revision. Blood Press Monit 2010; 15: 2338.
  • 21
    Stergiou G, Karpettas N, Atkins N, O’Brien E. European Society of Hypertension International Protocol for the validation of blood pressure monitors: a critical review of its application and rationale for revision. Blood Press Monit 2010; 15: 3948.
  • 22
    O’Brien E, Atkins N. Can improved software facilitate the wider use of ambulatory blood pressure measurement in clinical practice? Blood Press Monit 2004; 9: 23741.
  • 23
    O’Brien E. Ambulatory blood pressure measurement: a trove of hidden gems. Hypertension 2006; 48: 3645.
  • 24
    McGowan N, Atkins N, O’Brien E, Padfield P. Computerised reporting improves the clinical use of ambulatory blood pressure measurement. Blood Press Monit 2010; 15: 11523.
  • 25
    O’Brien E. Assessment of circadian cardiovascular risk with ambulatory blood pressure measurement. In: ManciaG, ed. Manual of Hypertension of the European Society of Hypertension. Abingdon, UK: Taylor and Francis, 2007, 4860.
  • 26
    Owens P, Atkins N, O’Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Hypertension 1999; 34: 26772.
  • 27
    Gerin W, Ogedegbe G, Schwartz JE et al. Assessment of the white coat effect. J Hypertens 2006; 24: 6774.
  • 28
    Verdecchia P, O’Brien E, Pickering T et al. When to suspect white coat hypertension? Statement from the working group on blood pressure monitoring of the European Society of Hypertension. Am J Hypertens 2003; 16: 8791.
  • 29
    Mule G, Nardi E, Cottone S et al. Relationships between ambulatory white coat effect and left ventricular mass in arterial hypertension. Am J Hypertens 2003; 16: 498501.
  • 30
    Owens PE, Lyons S, Rodriguez S, O’Brien ET. Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ damage? J Hum Hypertens 1998; 12: 7438.
  • 31
    O’Brien E. Unmasking hypertension. Hypertension 2005; 45: 4812.
  • 32
    Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 84653.
  • 33
    Calvo C, Hermida RC, Ayala DE et al. The ‘ABPM effect’ gradually decreases but does not disappear in successive sessions of ambulatory monitoring. J Hypertens 2003; 21: 226573.
  • 34
    O’Brien E. Sleepers v non-sleepers: a new twist in the dipper/non-dipper concept. Hypertension 2007; 49: 76970.
  • 35
    Owens P, Lyons S, O’Brien E. Ambulatory blood pressure in the hypertensive population: patterns and prevalence of hypertensive sub-forms. J Hypertens 1998; 16: 173543.
  • 36
    Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation 1998; 98: 18927.
  • 37
    Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 75764.
  • 38
    Mason PJ, Manson JA, Sesso HD et al. Blood pressure and risk of secondary cardiovascular events in women: the women’s antioxidant cardiovascular study (WACS). Circulation 2004; 109: 16239.
  • 39
    Pickering TG, Davidson D, Gerin W, Schwartz JE. Masked hypertension. Hypertension 2002; 40: 7956.
  • 40
    Bursztyn M, Mekler J, Wachtel N, Ben-Ishay D. Siesta and ambulatory blood pressure monitoring. Comparability of the afternoon nap and night sleep. Am J Hypertens 1994; 7: 21721.
  • 41
    Stergiou GS, Malakos JS, Zourbaki AS, Achimastos AD, Mountokalakis TD. Blood pressure during siesta: effect on 24-h ambulatory blood pressure profiles analysis. J Hum Hypertens 1997; 11: 12531.
  • 42
    Gomes MAM, Pierin AMG, Mion Jr D. The effect of siesta in parameters of cardiac structure and in interpretation of ambulatory arterial blood pressure monitoring. Arq Bras Cardiol 2000; 74: 3148.
  • 43
    Pickering TG. Isolated diastolic hypertension. J Clin Hypertens 2003; 5: 4113.
  • 44
    Staessen J, Bulpitt CJ, Fagard R et al. Reference values for the ambulatory blood pressure and the blood pressure measured at home: a population study. J Hum Hypertens 1991; 5: 35561.
  • 45
    Stolarz K, Staessen JA, O’Brien E. Night-time blood pressure—dipping into the future? J Hypertens 2002; 20: 21313.
  • 46
    O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet 1988; 2: 397.
  • 47
    Ohkubo T, Hozawa A, Yamaguchi J et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama Study. J Hypertens 2002; 20: 21839.
  • 48
    Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26: 17789.
  • 49
    Metoki H, Ohkubo T, Kikuya M et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama Study. Hypertension 2006; 47: 14954.
  • 50
    Smirk FH. Observations on the mortality of 270 treated and 199 untreated retinal grade I and II hypertensive patients followed in all instances for five years. N Z Med J 1964; 63: 41343.
  • 51
    Rachmani R, Shenhav G, Slavachevsky I, Levy Z, Ravid M. Use of a mild sedative helps to identify true non-dippers by ABPM: a study in patients with diabetes mellitus and hypertension. Blood Press Monit 2004; 9: 659.
  • 52
    Palatini P. Non-dipping in hypertension: still a challenging problem. J Hypertens 2004; 22: 226972.
  • 53
    Ben-Dov IZ, Ben-Arieh L, Mekler J, Bursztyn M. Blood pressure dipping is reproducible in clinical practice. Blood Press Monit 2005; 10: 7984.
  • 54
    Chaves H, Campello de Souza FM, Krieger EM. The reproducibility of dipping status: beyond the cutoff points. Blood Press Monit 2005; 10: 2015.
  • 55
    Mousa T, El-Sayed MA, Motawea AK, Salama MA, Elhendy A. Association of blunted nighttime blood pressure dipping with coronary artery stenosis in men. Am J Hypertens 2004; 17: 97780.
  • 56
    Bellelli G, Frisoni GB, Lucchi E et al. Blunted reduction in night-time blood pressure is associated with cognitive deterioration in subjects with long-standing hypertension. Blood Press Monit 2004; 9: 716.
  • 57
    Cicconetti P, Morelli S, Ottaviani L et al. Blunted nocturnal fall in blood pressure and left ventricular mass in elderly individuals with recently diagnosed isolated systolic hypertension. Am J Hypertens 2003; 16: 9005.
  • 58
    Hoshide S, Kario K, Hoshide Y et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 2003; 16: 4348.
  • 59
    Fan HQ, Li Y, Thijs L et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from10 populations. J Hypertens 2010; 28: 203645.
  • 60
    Floras JS. Antihypertensive treatment, myocardial infarction, and nocturnal myocardial ischaemia. Lancet 1988; 2: 9946.
  • 61
    Kikuya M, Ohkubo T, Asayama K et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 2005; 45: 2405.
  • 62
    Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 53946.
  • 63
    Ingelsson E, Björklund-Bodegård K, Lind L, Arnlöv J, Sundström J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 2006; 295: 285966.
  • 64
    O’Brien E, Murphy J, Tyndall A et al. Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank Study. J Hypertens 1991; 9: 35560.
  • 65
    Giles T. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2005; 23(suppl 1): S359.
  • 66
    Giles TD. Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens 2006; 24(suppl 2): S116.
  • 67
    Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 14016.
  • 68
    Marfella R, Siniscalchi M, Nappo F et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18: 30818.
  • 69
    Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895905.
  • 70
    Rothwell PM, Howard SC, Dolan E et al. on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 46980.
  • 71
    Dolan E, O’Brien E. Blood pressure variability: clarity for clinical practice. Hypertension 2010; 56: 17981.
  • 72
    Dolan E, Thijs L, Li Y et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension 2006; 47: 36570.
  • 73
    Uallachain GN, Murphy G, Avalos G. The RAMBLER study: the role of ambulatory blood pressure measurement in routine clinical practice: a cross-sectional study. Ir Med J 2006; 99: 2769.
  • 74
    Banegas JR, Segura J, Sobrino J et al. Effectiveness of blood pressure control outside the medical setting. Hypertension 2007; 49: 628.
  • 75
    Millar Craig MW, Kenny D, Mann S, Balasubramanian V, Raftery EB. Effect of once-daily atenolol on ambulatory blood pressure. BMJ 1979;i:2378.
  • 76
    Floras JS, Jones JV, Hassan MO, Sleight P. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol. BMJ 1982; 285: 138792.
  • 77
    Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004; 22: 43545.
  • 78
    Oliver JJ, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010; 56: 627.
  • 79
    Geiger H, Barranco E, Gorostidi M et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens (Greenwich) 2009; 11: 32432.
  • 80
    Barrios V, Brommer P, Haag U, Calderon A, Escobar C. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy. A randomized, double-blind, parallel-group, multicentre study. Clin Drug Invest 2009; 29: 42739.
  • 81
    Rump LC, Girerd X, Sellin L, Stegbauer J. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens 2010; 110. Advance online publication, 25 November 2010; doi: 10.1038/jhh.2010.105 [Epub ahead of print].
  • 82
    Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple Therapy With Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide in Adult Patients With Hypertension: the TRINITY Multicenter, Randomized, Double-Blind, 12-Week, Parallel-Group Study. Clin Ther 2010; 32: 125269.
  • 83
    Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens Advance online publication, 25 November 2010; doi: 10.1038/jhh.2010.104 [Epub ahead of print].
  • 84
    Chrysant SG, Lee J, Melino M, Karki S, Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010; 24: 7308.
  • 85
    Chrysant SG, Murray AV, Hoppe UC et al. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Curr Med Res Opin 2010; 26: 28419.
  • 86
    Böhm M, Baumhäkel M, Mahfoud F, Werner C. From Evidence to Rationale: Cardiovascular Protection by Angiotensin II Receptor Blockers Compared with Angiotensin-Converting Enzyme Inhibitors. Cardiology 2010; 117: 16373.
  • 87
    Appel LJ, Wright JT, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 91829.
  • 88
    Wright JT, Lacourcière Y, Samuel R, Zappe D, Purkayastha D, Black HR. 24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. J Clin Hypertens (Greenwich) 2010; 12: 83340.
  • 89
    Lv Y, Zou Z, Chen G, Jia H-X, Zhong J, Fang W-W. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 2010; 15: 195204.
  • 90
    Punzi H, Neutel JM, Kereiakes DJ et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010; Aug 4(4): 209–21.
  • 91
    Bakris GL, Lindholm LH, Black HR et al. Divergent results using clinic and ambulatory blood pressures. Report of a darusentan–resistant hypertension trial. Hypertension 2010; 56: 82430.
  • 92
    White WB, Littlejohn TW, Majul CR et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1–2 hypertension. Blood Press Monit 2010; 15: 20512.
  • 93
    Parati G, Ocho JE, Ramos C, Hoshide S, Lonati L, Bilo G. Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. Ther Adv Cardiovasc Dis 2010; 4: 30113.
  • 94
    Eguchi K, Hoshide S, Kabutoya T, Shimada K, Kario K. Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients? Blood Press Monit 2010; 15: 30811.
  • 95
    Malacco E, Omboni S, Volpe M, Auteri A, Zanchetti A on behalf of the ESPORT Study Group. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens 2010; 28: 234250.
  • 96
    Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 125566.
  • 97
    Kabakci G, Kaya BE, Tulumen E et al. The efficacy and safety of irbesartan in primary hypertension even if a dose is missed: results from the NO PROBLEM Study. Blood Press 2010; 1: 59.
  • 98
    Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz S, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–aldosterone system. J Hypertens 2010; 28: 232935.
  • 99
    US Food and Drug Administration, International Conference on Harmonisation (ICH). Guidance on statistical principles for clinical trials; availability. Federal Reg 1998;63:4958398. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073147.pdf (Accessed 14 January 2011).
  • 100
    European Medical Agency, Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment of hypertension. London, 18 November 2010 EMA/238/1995/Rev. 3. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/12/WC500100191.pdf (Accessed 14 January 2011).
  • 101
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 14553.
  • 102
    Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med 2010; 363: 98.
  • 103
    Dolan E, Stanton A, Caulfield M et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009; 27: 87685.
  • 104
    Mancia G, Omboni S, Parati G et al. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001; 19: 175563.
  • 105
    Lederballe-Pedersen O, Mancia G, Pickering T et al. ; VALUE trial group. Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. J Hypertens 2007; 25: 70712.
  • 106
    Schillaci G, Parati G. Determinants of blood pressure variability in youth: at the roots of hypertension. J Hypertens 2010; 28: 660.
  • 107
    Eguchi K, Ishikawa J, Hoshide S et al. Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009; 22: 4651.
  • 108
    Pierdomenico SD, Di Nicola M, Esposito AL et al. Prognostic value of different indices of blood pressure variability in hypertensive. Am J Hypertens 2009; 22: 8427.
  • 109
    Bjorklund K, Lind L, Zethelius B, Berglund L, Lithell H. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. J Hypertens 2004; 22: 16917.
  • 110
    Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 7128.
  • 111
    Verdecchia P, Porcellati C, Schillaci G et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793801.
  • 112
    Staessen JA, Hansen TW, Birkenhäger WH. Added VALUE of an ancillary study on ambulatory blood pressure monitoring. J Hypertens 2007; 25: 5135.
  • 113
    Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38: E2832.
  • 114
    Sega R, Facchetti R, Bombelli M et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 177783.
  • 115
    Boggia J, Li Y, Thijs L et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007; 370: 121929.
  • 116
    Pogue V, Rahman M, Lipkowitz M et al. for the African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009; 53: 207.
  • 117
    Li Y, Thijs L, Hansen TW et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension 2010; 55: 10408.
  • 118
    Kario K. Morning surge in blood pressure and cardiovascular risk evidence and perspectives. Hypertension 2010; 56: 76573.
  • 119
    Moutsatsos GD. More hype than HOPE. Hypertension 2003; 41: e4.